Filing Details

Accession Number:
0001144204-14-008800
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-13 20:30:58
Reporting Period:
2011-09-30
Filing Date:
2014-02-13
Accepted Time:
2014-02-13 20:30:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1335103 Protea Biosciences Group Inc. NONE Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1529511 P Leonard Harris 955 Hartman Run Road
Morgantown WV 26507
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-09-30 166,667 $250,001.00 1,773,657 No 4 P Direct
Common Stock Acquisiton 2013-07-23 387,334 $193,667.00 2,160,991 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option Acquisiton 2006-06-07 100,000 $80,000.00 100,000 $0.80
Common Stock Stock Option Acquisiton 2010-09-17 100,000 $150,000.00 100,000 $1.50
Common Stock Warrant Acquisiton 2010-10-18 100,000 $200,000.00 100,000 $2.00
Common Stock Warrant Acquisiton 2011-09-30 83,333 $0.00 83,333 $2.00
Common Stock Stock Option Acquisiton 2013-03-22 218,750 $120,313.00 218,750 $0.55
Common Stock Convertible Note Disposition 2013-07-23 387,334 $193,667.00 0 $0.50
Common Stock Warrant Acquisiton 2013-07-23 290,501 $319,551.00 290,501 $1.10
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
678,334 2006-06-07 2016-06-07 No 4 A Direct
778,334 2010-09-01 2017-09-01 No 4 A Direct
878,334 2010-10-18 2015-10-18 No 4 P Direct
961,667 2011-09-30 2016-09-30 No 4 P Direct
1,180,417 2013-03-22 2023-03-22 No 4 A Direct
1,047,083 2013-07-23 2013-07-23 No 4 C Direct
1,337,584 2018-07-23 2018-07-23 No 4 P Direct
Footnotes
  1. On September 30, 2011, Leo Harris (the "Reporting Person") acquired 166,667 shares of common stock and warrants to purchase 83,333 shares of common stock for an aggregate purchase price of $25,000.
  2. On June 30, 2013, pursuant to the terms and conditions of a Conversion Agreement, dated June 18, 2013 (the "Conversion Agreement") the Reporting Person converted the Notes (as defined below) into 387,334 shares of common stock, in connection with the conversion of convertible promissory notes (each a "Note" and collectively, the "Notes") issued to the Reporting Person in an aggregate amount equal to $193,667.14 including principal and interest.The Notes accrue simple interest at the rate of 10% per annum and were initially convertible into shares of common stock at a conversion rate of $2.00 per share at any time prior to payment in full of the principal and interest due under the Notes. On March 22, 2013, the board of directors of the Company agreed to reduce the conversion rate of the Notes to $0.50 per share. The Notes were converted into shares of common stock of the Company in accordance with the Conversion Agreement on June 30, 2013.
  3. Pursuant to the Conversion Agreement, upon conversion of the Notes, the Company agreed to issue a warrant to purchase 75% of the number of shares into which the Notes are convertible.
  4. Represents shares vested as of February 10, 2014.
  5. Reflects the expiration of previously reported warrants to purchase 133,334 shares of common stock.